Moderna’s COVID-19 vaccine provides antibodies for at least 6 months after the second dose but fades for older persons

Primary tabs

Wed, 2021-04-07 19:14 — mike kraft

Moderna's COVID Vax Produces Antibody Responses 6 Months Later But neutralizing activity declined over time, and not equally among age groups Molly Walker medpagetoday

Antibodies persisted 6 months after the second dose of Moderna's COVID-19 vaccine in younger and middle-age adults, but were diminished in older adults when using more sensitive assays, according to data from an ongoing phase I trial.

Antibody activity was high across groups at day 209, but assessment with a "live virus" neutralization test found geometric mean titers declined more over time in participants ages 56 and older compared with adults ages 18-55, reported Mehul Suthar, PhD, of Emory University School of Medicine in Decatur, Georgia, and colleagues in a correspondence piece in the New England Journal of Medicine.

They noted the durability of protection is currently unknown, and examined binding and neutralizing antibodies elicited by the Moderna COVID-19 vaccine in 33 healthy adult participants in an ongoing phase I trial, who were stratified by age. They measured responses at 180 days after the second dose of vaccine, or day 209, using three distinct serologic assays.

Suthar's group found nearly all participants "had detectable activity in a pseudovirus neutralization assay," and all participants had detectable activity on the "more sensitive live-virus focus-reduction neutralization mNeon-Green test," but it was this assay for which geometric mean titers were lower in older adults compared with adults ages 18-55.

In that assay, neutralizing activity in the older groups declined approximately 10-fold at 6 months from the peak 14 days after the second vaccine dose; in those 18-55, activity was down by roughly half. But activity levels in the older groups remained more than 10-fold above pre-vaccination baseline at the 6-month mark. ...

Country / Region Tags:

General Topic Tags: